Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 31, 2019updated 09 Aug 2019 9:40am

Janssen unblinds Phase III TITAN study for prostate cancer

Janssen Pharmaceutical Companies of Johnson & Johnson has unblinded the Phase lll TITAN trial investigating Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

Janssen Pharmaceutical Companies of Johnson & Johnson has unblinded the Phase III TITAN trial investigating Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

The development follows recommendation provided by an Independent Data Monitoring Committee (IDMC) and a pre-planned evaluation that showed that the trial achieved its dual primary endpoints of improving radiographic progression-free survival (rPFS) and overall survival (OS).

IDMC suggested that patients in the placebo plus ADT group should be allowed to cross over to treatment with Erleada plus ADT. However, the TITAN trial will continue to follow patients for OS and long-term safety results.

Janssen Research & Development Oncology Clinical Development vice-president Margaret Yu said: “The TITAN study was designed to evaluate the efficacy and safety of Erleada in combination with androgen deprivation therapy in patients with newly-diagnosed metastatic castration-sensitive prostate cancer, regardless of the extent of their disease.

“We look to continue to build upon our understanding of Erleada for patients with metastatic prostate cancer.”

“We look to continue to build upon our understanding of Erleada for patients with metastatic prostate cancer as there remains a significant unmet need for additional treatment options.”

Janssen plans to submit applications seeking regulatory approval of Erleada based on results from the TITAN trial within this year.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

TITAN features a randomised, placebo-controlled, double-blind design. It includes more than 1,050 men who were newly diagnosed with metastatic disease, irrespective of prognostic risk, volume of disease, prior treatment with docetaxel or treatment of localised disease.

Patients with mCSPC were randomised to be treated with either Erleada plus ADT or placebo plus ADT as part of the trial.

The trial’s secondary endpoints comprise time to chemotherapy, time to pain progression, time to chronic opioid use, and time to skeletal-related event.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU